Dogwood Therapeutics, Inc.

NasdaqCM:DWTX Stock Report

Market Cap: US$5.3m

Dogwood Therapeutics Balance Sheet Health

Financial Health criteria checks 4/6

Dogwood Therapeutics has a total shareholder equity of $3.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $3.6M and $500.1K respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$3.02m
EquityUS$3.14m
Total liabilitiesUS$500.08k
Total assetsUS$3.64m

Recent financial health updates

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Aug 24
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?

May 11
Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?

Recent updates

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Aug 24
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?

May 11
Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?

Virios Therapeutics slides 11% postmarket on proposed stock offering

Sep 19

Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07

Aug 11

Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jun 25
Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Mar 09
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Nov 02
Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jul 19
Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study

Jun 04

Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Mar 31
Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Virios Therapeutics gains 10% on research deal in irritable bowel syndrome

Feb 01

Virios Therapeutics prices IPO at $10

Dec 17

Financial Position Analysis

Short Term Liabilities: DWTX's short term assets ($3.6M) exceed its short term liabilities ($500.1K).

Long Term Liabilities: DWTX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: DWTX is debt free.

Reducing Debt: DWTX currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DWTX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: DWTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.9% each year


Discover healthy companies